Stage N Hodgkin's disease is relatively uncommon subgroup of Hodgkin's disease; a large recent survey reported stage IV to comprise 8.6% of clinically staged and 13.4% of pathologically staged patients'. The most common sites of extranodal involvement are the spleen, lung,liver, bone and bone marrow; involvement of other extranodal tissues is uncommon'', This discussion concerns an exceptionally rare presentation of the disease.
Case report A 56-year-old man presented to the referring hospital with a six month history of progressive, painless swellings in the right scrotum and right axilla. There was no history of night sweats, fever or weight loss. Excision biopsies of the right 
NA.
On referral to the Royal Marsden Hospital, haemoglobin, total and differential leucocyte count, platelet count and erythrocyte sedimentation rate were normal. Serum urea, creatinine, alkaline phosphatase, alanine transaminase, bilirubin, ')'-glutamyltransferase and immunoglobulin electrophoresis were within the normal laboratory range. Bone marrow aspirate and trephine examinations showed no evidence of infiltration. Chest X-ray, intravenous urography, bipedal lymphography, ultrasonography and computed tomography of abdomen and pelvis were normal. Ultrasound examination of the right testis demonstrated an irregular lobulated 1.5 em echo poor lesion in the upper pole suggestive of testicular involvement by Hodgkin's lymphoma.
Complete remission confirmed by testicular ultrasound was achieved following the second of six, 28 day cycles of combination chemotherapy. The flrst four courses comprised Chlorambucil E! mg/m", procarbazine 100 mg/m 2 and prednisolone 40 mg/m" orally, daily for 14 days. Vinblastine 6 mg/m 2 was given intravenously days 1 and 8 3 The Royal Society of Medicine toxicity was otherwise minimal and comprisedmild peripheral neuropathy and transient unilateral gynaecomastia following completion of chemotherapy. The patient remains diseasefree three years following completion of chemotherapy.
Discussion
Lymphomatous involvement of the testis or adnexae is almost invariably non-Hodgkin and comprises 5-10% of testicular neoplasms overall'. To our knowledge only one other case of testicular and epididymal Hodgkin's disease has been reported describing a 79-year-oldmale patient who presented with extensive disease involving the testis, epididymis, spermatic cord and retroperitoneum. Histological examination at autopsy revealed the presence of Hodgkin's disease with Reed-Sternberg cells".
Since most patients have orchidectomy, management of primary testicular neoplasia is rarely complicated by the possible existence of a blood-testis barrier impeding penetration of chemotherapeutic agents. A blood-testis barrier has been demonstrated in several animal models and electron microscopy has revealed intercellular structural barriers", Distinct physiological barriers in both the seminiferous tubules and cauda epididymis of hamsters have been shown by a micropuncture technique". There are, however, species specific differences in selective passage of substances into these structures", Chemotherapeutic agents are selectively excluded from parts of the testis. Radiolabelled cyclophosphamide and vincristine have been shown to readily cross the 'barrier' in the Sprague.Dawley rat 9 ; however, actinomycin D is excluded from the testis'".
Orchidectomy is important for the diagnosis of testicular neoplasia and usually precedes systemic chemotherapy for metastatic disease. A differential response of primary testicular tumour and metastatic lesions has been demonstrated in patients with disseminated germ-cell tumours treated with the testis in situ ll • 12 • Evidence opposingthe existence of a significant blood-testis barrier includes the reduction offertility followingtreatment with cytotoxic chemotherapy particularly resulting from the use of alkylating agents and cisplatin'", Furthermore, histological examination of gonadal autopsy specimens has revealed reduced spermatogenic activity and increased interstitial fibrosis in treated leukaemic patients".
Testicular involvement as first evidence of relapse of acute childhood leukaemia following successful remission induction has been reported to occur in 16% of patients". An early report suggested that the development of testicular leukaemia may not necessarily herald systemic relapse and proposed the existence of a blood-testis barrier impairing penetration of chemotherapeutic agents", However, more recent studies indicate that testicular relapse is a manifestation of occult systemic relapse and emphasize the importance of reinduction systemic chemotherapy'J-".
In conclusion it would appear that selective, species specific, blood-testis and blood-epididymis barriers may exist, however, their relevance to the successful treatment of testicular neoplasia in man remains inconclusive.
The ChlVPP combination chemotherapy regimen has been reported to produce an 83% overall four year survival in patients with stage IVA Hodgkin's disease". The case we have described presented with small volume stage IVA Hodgkin's disease involving the epididymis and testis and Journal of the Royal Society of Medicine Volume 82 September 1989 559 treatment was undertaken with the testis in situ using combination chemotherapy. Since the patient remains in complete remission three years after treatment, the longterm prognosis is very good'",
